Matrix metalloproteases and their tissue inhibitors in non-alcoholic liver fibrosis of human immunodeficiency virus-infected patients

doi:10.5501/wjv.v6.i2.36

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8309)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-6) series.

Item

Count

PDF

496

WORD

317

HTML

2581

Tables (1-6)

178

Sum=3572

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

987

Download

1231

Sum=2218

Publishing Process of This Article

Item

Count

Browse

998

Download

1521

Sum=2519

May 12, 2017 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Virol. May 12, 2017; 6(2): 36-45
Published online May 12, 2017. doi: 10.5501/wjv.v6.i2.36

Table 2 Genotypic frequencies of different single nucleotide polymorphisms according to liver fibrosis ≥ F2 and hepatitis C virus status

SNP	Genotype	No fibrosis n (%)	Fibrosis n (%)	P value	HIV mono-infected n (%)	HIV/HCV coinfected n (%)	P value
MMP-1 -1607 1G/2G	1G1G	14 (20.3)	4 (16.7)	0.9	9 (16.1)	9 (24.3)	0.6
	1G2G	13 (18.8)	5 (20.8)		12 (21.4)	6 (16.2)
	2G2G	42 (60.9)	15 (62.5)		35 (62.5)	22 (59.5)
MMP-8 -799C/T	CC	30 (27.0)	6 (22.2)	0.6	25 (26.3)	11 (25.5)	1
	CT	47 (42.4)	10 (37.0)		39 (41.1)	18 (41.9)
	TT	34 (30.6)	11 (40.8)		31 (32.6)	14 (32.6)
MMP-9 -1562 C/T	CC	78 (81.2)	28 (84.8)	0.6	61 (83.6)	45 (80.4)	0.6
	CT	18 (18.8)	5 (15.2)		12 (16.4)	11 (19.6)
	TT	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)
MMP-13 -77A/G	AA	89 (74.8)	21 (61.8)	0.14	70 (72.9)	40 (70.2)	0.7
	AG	30 (25.2)	13 (38.2)		26 (27.1)	17 (29.8)
	GG	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)
TNF-α -308 G/A	AA	11 (11.3)	4 (11.8)	0.5	7 (9.5)	8 (14.0)	0.7
	AG	62 (63.9)	18 (52.9)		46 (62.1)	34 (59.6)
	GG	24 (24.7)	12 (35.3)		21 (28.4)	15 (26.3)
CCR5-Δ32	wt/wt	96 (80.0)	30 (88.2)	0.27	77 (79.4)	49 (86.0)	0.3
	wt/Δ32	24 (20.0)	4 (11.8)		20 (20.6)	8 (14.0)
	Δ32/Δ32	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)

SNP: Single nucleotide polymorphisms; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; MMP: Matrix metalloprotease.

Citation: Collazos J, Valle-Garay E, Suárez-Zarracina T, Montes AH, Cartón JA, Asensi V. Matrix metalloproteases and their tissue inhibitors in non-alcoholic liver fibrosis of human immunodeficiency virus-infected patients. World J Virol 2017; 6(2): 36-45
URL: https://www.wjgnet.com/2220-3249/full/v6/i2/36.htm
DOI: https://dx.doi.org/10.5501/wjv.v6.i2.36